sgen

An attempt was made to load an assembly with an incorrect format SGEN Error in Visual Studio

I came across this annoying error when trying to compile my solution for 64-bit. This occurs when a project references a webservice and also references a 64-bit assembly. If you have serialization set to Auto or On for the first assembly then this error will pop out so you need to turn serialization off.

2

When: January 13, 2012

Where: Southville Foreign University

It was the Southville Global Education Network’s (SGEN) Research Review launch. It’s an event where they showcased their research about certain relevant topics.

The picture on the left is of Deandro Almariego, Johnny Malvar, Me, and Sir. Albert Tijam. Dean, Johnny, and I were tasked to sing for this event by the school’s music group, Cradle. We didn’t know the people were of the likes: The owner of the Southville brand, the director of CHED, deans from different Southvilles.

As we learned the status of the people, we all got a little intimidated. But in the end we pulled it off. 

The picture to the right is me singing “All of Me.”

2

A few weeks after our first post on SGEN, it actually broke the downtrend channel initiated in January when its drug was approved in Europe. And since then, it did not disappoint, going up almost 40% in a new bullish channel, to new all time highs.

With a crucial FDA meeting approaching on Thursday, there has been a spike in put trading.

The Oncologic Drugs Advisory Committee (ODAC) meeting tomorrow will be a major milestone for the company. SGEN is requesting either full or accelerated approval for two indications: relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large cell lymphoma. ODAC’s decisions will likely seal the fate of SGN-35 (brentuximab vedotin, Adcetris).

The stock suffered on 07/12 as the FDA may limit the usage of the drug for the Hodgkin indication for only patients that had autologous stem cell transplants. Additional concerns are with the safety profile of the drug and the fact that the supporting trials for each indication are single-arm studies, which the FDA tends to view unfavorably.

Given the recent rally, any bad news – most likely a delay – about approval of Adcetris would certainly hurt SGEN badly. Alternatively, if ODAC recommends approval for either indication, the rally could certainly continue.